Multiple myeloma can relapse two or more times, and tends to become more aggressive and more treatment-resistant with each ...

For the first time, patients with abnormal cells detected in their bone marrow have a treatment option before the condition ...

Since the beginning of this century, advances in understanding the biology of multiple myeloma have transformed the disease ...

Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of ...

You don’t expect to break a rib while doing light housekeeping. Similarly, you wouldn’t think your worsening back pain might be caused by a type of blood cancer. However, these are among classic ...

The FDA has approved daratumumab and hyaluronidase-fihj monotherapy as treatment for adults with high-risk smoldering ...

The FDA approves Johnson & Johnson's Darzalex Faspro for high-risk smoldering multiple myeloma and Caplyta as an add-on ...

MM often goes undetected until its later stages because it presents with non-specific symptoms, including fatigue, weight loss, bone pain, and recurrent infections. 2,3 However, better awareness, ...

While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...

Kimberly Alexander's caregiving experience revealed a lack of awareness and support for multiple myeloma, especially in the ...

The approval for HR-SMM was based on data from the phase 3 AQUILA study, which evaluated Darzalex Faspro in adults aged 31 years and older with HR-SMM.

The FDA approved Darzalex Faspro for the treatment of adults with high-risk smoldering multiple myeloma. The U.S. Food and ...